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Cattle are highly valued in Africa, and in the eastern, central and
southern regions of the continent, they play diverse roles in the liveli-
hoods and economies of peoples and countries. So when a highly fatal
disease of cattle appears to be interfering with the exploitation of this
diverse livestock resource, the call for a sustainable solution is loud. So
it has been with the call for a vaccine to protect cattle against East
Coast fever (ECF).
ECF is tick-borne and indigenous to the region, probably originally a
parasite of the Cape buffalo (Syncerus caffer). It was ﬁrst described in
eastern Africa as Amakebe by Bruce et al. (1910) [1], where it had been
endemic and apparently recognised for centuries as a relatively mild
disease of calves. Surprisingly, it was only when tick-infested cattle
were exported by boat from eastern to southern Africa in 1901 and
1902, and the disease appeared in what is now Zimbabwe, that the
disease became widely recognised [2]. Rinderpest had earlier swept
down through southern Africa, wiping out over 2.5 million cattle in
South Africa alone, before it was eradicated from that country in 1899.
As a result of rinderpest and of the effects of the Boer war (1899–
1902), the cattle populations of southern Africa had become depleted,
and were inadequate to meet the multiple needs of the region [2]. As
a result, cattle were imported from many sources, including Kenya
and Tanzania, where ECF, in its milder form in the resistant indigenous
animals of the region, hadbeen existing almost unnoticed for generations.
It was only when the early European settlers started to arrive in eastern
Africa, importing exotic cattle breeds, that the disease was recognised
there, and it was not until 1911 that the endemic disease in eastern. This is an open access article underAfrica and the epidemic highly fatal disease in southern Africa were
found to be one and the same [3].
This narrative describes the story behind the development of a live
vaccine against ECF, probing the technological achievements which
laid the groundwork for the innovation, the institutional settings in
which this occurred, and the political dynamic of both over the last
50 years. It also analyses the indicators of success and the many quali-
ﬁers of these, the impacts that the emerging technology has had, both
in positive and negative terms, andmaps the key contributors andmile-
stones on the research to impact pathway.
2. Livestock disease priorities in Eastern Africa in the evolving social
and political landscape
2.1. The legacy of colonial livestock systems and accompanying research
imperatives
Somewhat surprisingly in the context of 2016, the fundamental and
widespread belief in Kenya in the late 1960s and early 1970s was that
the priority disease of cattle in easternAfricawas ECF.While this disease
undoubtedly continues to feature in any livestock disease-ranking in
Kenya and indeed in other countries of the eastern and southern
African region, in today's context we would likely ask the questions:
“priorities to whom?”…and…. “on what evidence?” The evidence that
was available at the time to answer these unasked questions was
derived almost entirely from themore commercially orientated livestock
enterprises of the European settler community and the priorities of the
former colonial government and its veterinary services and diagnosticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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larly in Kenya, have been phenomenal over the past 35 years, and espe-
cially over the past 15 years or so; the trend in the highland regions has
been a progressive intensiﬁcation1 of smallholdermixed farming systems
in which livestock are central (see for example Van de Steeg et al., 2005)
[4]. In these systems tick-borne disease control has moved from a broad
public sector responsibility, administered through community cattle
dips, to farmer operated backpack application, spray race systems and
private dips, depending on the scale of the enterprise. This devolution of
responsibility has provided much more effective control of ECF, even in
the absence of a vaccine.
But it is not only the livestock production systems that have
changed; the animal disease research environment has had its own
dynamic. Looking back at the veterinary research landscape in Kenya
during the late 1960s and early 1970s, theperiod immediately following
independence, the already existing and competent disease research
infrastructure which had existed was replaced, at least for a decade or
so, by a wave of new technical assistance attempting to provide contin-
ued veterinary service and research support to post-colonial livestock
enterprises, and to train the new generation of African scientists. But
the story was not that simple.2.2. The changing institutional framework
During the latter part of the colonial era in eastern Africa, the main
centre of research on ECF and other tick-borne diseases (TBDs) was at
the East African Veterinary Research Organization (EAVRO). EAVRO
was one of ﬁve research organizations responsible to the East African
Agricultural and Fisheries Research Council, under the East African
High Commission (EAHC). The EAHC operated from 1948 to 1961,
then became the East African Common Services Organization (EACSO)
from 1961 to 1967, and ﬁnally the East African Community (EAC)
from 1967 to 1977. The EAC collapsed in 1977, (but was revived in
2000). The 1956/57 Annual Report of EAVRO stated that their laborato-
ries at Muguga North were completed towards the end of 1954 and
opened by the Governor of Kenya Sir Evelyn Baring on 21st February
1957. The staff listing contained some notable names, such as Walter
Plowright, who was to go on to receive the World Food Prize for his
work on rinderpest tissue culture vaccine development,2which contrib-
uted signiﬁcantly to the ultimate global eradication of rinderpest in
2011.
The tick-borne disease research group at the time was led by Steve
Barnett, with colleagues David Brocklesby and Peter Bailey, among sev-
eral others in the team. ECF was a major focus of their work, principally
studying the transmission and chemotherapy of the infection; some
research on immunisation of cattle had started which involved a
28-day therapy regimen of the antibiotic aureomycin following their
infestationwith ECF-infected ticks,whichwas perhaps theﬁrst successful
exploitation of an ITM approach undertaken at EAVRO.
In December 1963, just ﬁve years after the opening of EAVRO
at Muguga, Kenya gained its independence from the UK, and the UK
government continued its support to livestock disease research. In
1967 the United Nations Development Programme (UNDP) initiated
the funding of a 10-year research programme on tick-borne disease
research under the auspices of the Food and Agriculture Organisation
(FAO), based at EAVRO, Muguga.3 It was this FAO-administered1 FAO (2004) deﬁned intensiﬁcation as an increase in agricultural production per unit of
inputs (which may be labour, land, time, fertilizer, seed, feed or cash). For practical pur-
poses, intensiﬁcation occurs when there is an increase in the total volume of agricultural
production that results from a higher productivity of inputs, or agricultural production is
maintained while certain inputs are decreased (such as by more effective delivery of
smaller amounts of fertilizer, better targeting of plant or animal protection, and mixed
or relay cropping on smaller ﬁelds). The ethics of sustainable agricultural intensiﬁcation,
FAO, Rome. http://www.fao.org/docrep/007/j0902e/j0902e00.htm#Contents.
2 http://www.worldfoodprize.org/en/laureates/19871999_laureates/1999_plowright/.
3 http://www.fao.org/docrep/003/x6519e/x6519e00.htm.research programme which was ultimately responsible for developing
the ITM live vaccination against ECF.
While having as its objective the study of controlling ticks and
tick-borne diseases in general, the project placed special emphasis
on immunological work designed to control ECF by means of a vaccine.
The project started operations in May 1967 at the laboratories of
EAVRO, originally a project of three years duration but as a result of
two extensions it continued until the end of 1976, just prior to the
collapse of the EAC. With the collapse of the EAC in 1977, EAVRO
was absorbed into the Ministry of Agriculture and renamed the Vet-
erinary Research Department (VRD) and in 1986 it was brought
under the Kenya Agricultural Research Institute (KARI) as the Na-
tional Veterinary Research Centre (NVRC). Research on ECF contin-
ued at Muguga at the renamed NVRC. Importantly, despite the end
of FAO's important contributions to EAVRO, the organisation contin-
ued to be heavily committed to supporting research on ECF and other
TBDs in eastern and southern Africa for several decades to come, and
many of the subsequent regional discussion forums held were co-
ﬁnanced by FAO.
2.3. The birth of the CGIAR and ILRAD
Therewas substantial international interest in providing technical sup-
port to the newly independent countries of eastern Africa and elsewhere
during the years immediately following Kenya's independence in 1963.
The Ford and Rockefeller Foundations had helped launch the
International Rice Research Institute (IRRI) in the Philippines, and two
years later the two Foundations began discussing the possibilities of a cen-
tre concerned with improving the yield and quality of tropical food crops
other than rice; the International Institute of Tropical Agriculture (IITA)
was opened in 1967 near Ibadan, Nigeria [5]. This process gainedmomen-
tum and in 1970 the Rockefeller Foundation proposed a worldwide net-
work of agricultural research centres under a permanent secretariat.
Notably, this was coincident with the early years of the FAO programme
at EAVRO in Muguga. The concept was further supported and developed
by the World Bank, FAO and UNDP, and the Consultative Group for Inter-
national Agricultural Research (CGIAR) was established on May 19, 1971
to coordinate international agricultural research efforts aimed at reducing
poverty and achieving food security in developing countries.
A study had been commissioned by the Rockefeller Foundation to
explore the creation of a livestock disease research centre (McKelvey
and Pino, 1971) [6]. The CGIAR created an “African Livestock Subcom-
mittee”, which asked the Rockefeller Foundation to act as executing
agency in negotiations with the EAC for the establishment of an animal
disease research laboratory, to be knownas the International Laboratory
for Research on Animal Diseases (ILRAD) and to be located at EAVRO,
Muguga. At a meeting of the EAC Council on July 20th 1972 a decision
was taken that the EAC could not host an autonomous institution as
had been proposed, and the invitation to establish ILRAD within the
EAC was withdrawn. The subcommittee then agreed to pursue an alter-
native option of establishing ILRAD at Kabete outside Nairobi. The ﬁrst
step was to reopen negotiations with the Kenya Government, through
a letter from the then President of the World Bank, Robert McNa-
mara, to President Jomo Kenyatta. In the letter, reference was made
to earlier correspondence in which President Kenyatta had
expressed his interest in research on animal diseases in eastern Afri-
ca, and had offered facilities and support of the Kenya Government.
The letter mentioned that if and when a comprehensive animal pro-
duction and health centre should be established for tropical Africa
(referring to parallel negotiations going on at the time with the Im-
perial Ethiopian government on the establishment of the Interna-
tional Livestock Centre for Africa -ILCA), there would be the
possibility of a link between or even the integration of these two cen-
tres. Ironically in January 1995 the two CGIAR institutes of ILRAD,
based in Nairobi, Kenya, and ILCA, based in Addis Ababa, Ethiopia,
were united as the International Livestock Research Institute (ILRI).
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FAO research project at EAVRO, Muguga.
3. The technology/innovation
3.1. East Coast fever, the tick-borne malaria of cattle
ECF is a tick-transmitted disease of cattle which causes major
economic losses throughout eastern, central and southern Africa,
where it has been regarded as one of themost serious constraints to im-
proving the livestock industries of the region. The disease can cause
high mortality in cattle, particularly affecting improved dairy and beef
cattle, as well as in zebu cattle in pastoralist areas and ranches. There
is an extensive literature on the disease (see for example Norval et al.,
1992 [7]; Perry and Young, 1993 [8]; Lawrence et al., 2004 [9]; and
Gachohi et al., 2012 [10]). An economic impact assessment of the disease
was undertaken in 1989 by Mukhebi et al., (1992) [11], which estimated
the total regional losses due to the disease to be US$ 168 million, which
included an estimated mortality of 1.1 million cattle. Surprisingly, there
have been few follow-up studies to validate or update these estimates,
and as a result this ﬁgure is still regularly cited as the cost of the disease.
3.2. The innovation behind the live vaccine against ECF
Few theory-based strategies in human and veterinary medicine are
sounder than the use of vaccines to artiﬁcially induce population immu-
nity, and vaccine development and deployment has an outstanding suc-
cess record in the control (and eradication, in the case of smallpox and
rinderpest) of major infectious diseases.
On the speciﬁcs of applying this theory to immunization of cattle to
protect against the causal agent of ECF, there were several milestone
technical innovations which contributed to the development and success
of the Infection and Treatment (ITM) approach. These were:
• The ability to harvest Theileria parva sporozoites from batches of
infected Rhipicephalus appendiculatus ticks.
• The ability to preserve T. parva stabilates (cryopreserved sporozoite
preparations) in liquid nitrogen for extended periods of time without
affecting their infectivity. This allowed the administration of a uniform
and reproducible dose of infective material to cattle.
• The ability to induce sustained protective immunity in cattle through
the injection of T. parva stabilates in combination with long-acting
oxytetracycline treatment
• The identiﬁcation and combination into a single stabilate of three
parasite stocks (T. parva Muguga, T. parva Kiambu 5 and buffalo de-
rived T. parva Serengeti transformed), which became known as the
Muguga Cocktail (MC), which has been shown to afford very good
protection against T. parva, both in the laboratory and the ﬁeld in
many parts of eastern and central Africa, despite the wide diversity
of T. parva immunological strains found in the ﬁeld
• The adjustment of the dose of long acting oxytetracycline from20% to 30%
dramatically reduced the proportion of clinical reactors to ITM, allowing
the live vaccine to be more widely applied in countries of the region
• The preparation at ILRI in 1996 of a commercial scale batch of the MC at
the request of FAO and funded by FAO through a Technical Cooperation
Programme – TCP.4 These stabilates were therefore designated FAO 1
and FAO 2. A second commercial scale batch was produced again some
10 years later in 2007 at the request of the Inter-African Bureau of Animal
Resources of the African Union (AU/IBAR5). This stabilate was designated
ILRI 08.4 http://www.fao.org/technical-cooperation-programme/en/.
5 What was originally termed the Organisation for African Unity (OAU) was renamed
the African Union in 2002. Within the organisation sits the Inter-African Bureau of Animal
Resources (IBAR), established in 1951 as the Inter-African Bureau of Epizootic Diseases
(IBED.These technical innovationswere the result of numerous experiments
and trials, and for the speciﬁc details of the different studies undertaken
the reader is referred to the following reviews: Cunningham (1977)
[12]; Radley (1981) [13]; Norval et al. (1992) [7]; Uilenberg (1999)
[14]; Di Giulio et al., (2009) [15]; Yrjö-Koskinen et al., 2010 [16]; ILRI,
2014 [17].
The major features of these technical innovations are summarised
below.
Fundamental to the concept of immunization, it had been observed
that cattlewhich survive infection naturally develop long lasting immu-
nity, and this was demonstrated experimentally by Burridge at al.
(1972) [18], who showed that solid protection against homologous
challenge lasted for up to three and a half years in the absence of
reinfection.
Neitz (1953) [19] in Onderstepoort, South Africa, had earlier found
that when Theileria parva-infected ticks were applied to cattle that
were simultaneously treated with chlortetracycline (under the trade
name Aureomycin), the cattle underwent mild reactions and were
immune on challenge. The drug was administered intravenously at a
dosage rate of 10mg/kg, starting 24 h after tick infestation and continuing
on approximately alternate days for 2–3 weeks.
Subsequently, Brockelsby and Bailey (1962; 1965) [20,21] at EAVRO
in Kenya applied T. parva-infected ticks to cattle which then received
oral tetracycline at a dosage of 15 mg/kg, and they recommended the
use of this immunization technique in valuable exotic breeds of cattle.
This method was applied further by Jezierski et al. (1959) [22] in
Rwanda and Jarrett et al. (1969) [23] in Kenya.
Under the leadership of Matt Cunningham, the FAO project made a
breakthrough in the technique of ITM by the production of sporozoite
stabilates, the infectious stage of T. parva that is found in ticks, known
at the time as ground-up tick stabilates (GUTS). This allowed cattle to
be infected with a speciﬁc predetermined dose (Cunningham et al.,
1973) [24].
During the six-year period from 1971 to 1977, a series of experiments
was undertaken to reduce the amount of drug required to control infec-
tion and yet permit a protective immune response to develop. It was
found that two doses (10 mg/kg) of short acting oxytetracycline given
on days 0 and 4 would permit good protection with this immunization
regimen.
Amajor breakthrough camewith the introduction by the pharmaceu-
tical company Pﬁzer of a long-acting oxytetracycline product (Terramycin
LA, Pﬁzer, UK). The long-acting formulation, when given at a single dose
of 20mg/kg at the time of infectionwith the sporozoite stabilate, resulted
in the development of immunity to homologous T. parva stabilate
challenge with minimal clinical response.
A severe limitation to the effective immunization of cattle against
T. parva using ITM has been the recognition of different strains of
T. parva in the ﬁeld; this is particularly important in infections derived
from buffalo. It was quickly established that different immunogenic
stocks existed, and this led to the search for a “master” stock or stocks
which would induce broad protection in immunized animals (Mutugi
et al., 1990a) [25]. In a series of experiments, a combination of three
stocks (T. parva Muguga, T. parva Kiambu 5 and buffalo derived
T. parva Serengeti transformed), which were collectively given the
name the “Muguga Cocktail (MC)” [26], and was shown to afford very
good protection against T. parva, both in the laboratory and the ﬁeld in
many parts of eastern and central Africa [27,13,28].
During the ten years of the FAO project's life the following agencies
established cooperative support projects with EAVRO: Ministry of
Overseas Development, United Kingdom (latterly Overseas Development
Administration ODA); United States Department of Agriculture (USDA);
Pﬁzer International Incorporated; International Centre for Insect Physi-
ology and Ecology (ICIPE); International Development Research Centre
(IDRC) Canada; International Atomic Energy Agency (IAEA); Australian
Volunteer Service; Nufﬁeld Institute of Comparative Medicine, and the
Rockefeller Foundation.
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charging producers for each dose administered, were Lieve Lynen and
colleagues at VetAgro in Tanzania. The technique was introduced
there in 1993, initially restricted to the smallholder dairy sector, but
from 1998 it was made available to pastoralist communities in the
Arusha region of northern Tanzania [29,30,15]). Some initial problems
with severe clinical reactions to the immunization were solved by
raising the dose of simultaneously administered long-acting oxytetra-
cycline formulation from 20% to 30% [30].
4. The pathway from the development of the live vaccine technology
to its adoption, use and impact
4.1. The long and winding road, the scientiﬁc reticence, and the inevitable
politics
The feasibility of immunisation using the ITMmethodwas established
by Willi Neitz in South Africa in the 1950s, a theoretical approach using
oxytetracycline was established by Brocklesby and Bailey at EAVRO in
the 1960s, and a pragmatic and practical application of this method
using Pﬁzer's then newly emergent long-acting formulation of oxytetra-
cycline was developed by the FAO project at EAVRO in the 1970s. This
happened about 40 years ago, but it is only relatively recently that vaccine
production capacity has been established outside ILRI, and that vaccine
has been distributed in the different ECF-affected countries. What
happened in the interim? What were the other factors which helped or
hindered the application of this apparently simple technology? The trail
from innovation to impact is reviewed below.
4.2. The void following the end of the UNDP project
The very productive UNDP-sponsored research project at Muguga
ﬁnished in late 1976, winding up a most productive decade of intense
research, and also bringing to an end the impetus for translating the
live vaccine experimental successes into a product which could be
delivered. In addition, the EAC collapsed shortly afterwards in 1977,
bringing other institutional challenges to the research at Muguga. At
the time, ILRAD, initiated in late 1973 and with facilities ﬁnally
inaugurated in 1978, was going through its early establishment and
development years, and it too was having a set of teething problems.
These related ﬁrstly to its new role as an international research centre,
housed in a country desperate to further develop and sustain its own
veterinary research capacity on a par with the previous decade of FAO
contributions and before. Secondly there were problems of institutional
leadership; when Ross Gray became Director General (DG) in 1982 he
was the fourthDG in seven years. Theﬁrst, E. Sadun, died before assuming
ofﬁce. Sadun's successor, James Henson, resigned during his second term.
The third, Anthony Allison, was asked to resign after less than two years
(Lewin, 1982). Not a healthy start. Notably, Ross Gray went on to lead
ILRAD for almost 14 years until the institute was merged with ILCA in
January 1995 and ILRI was born.
ECF research continued at the NVRC in Muguga, but with much less
in thewayof funding andhuman resources. Funding support came from
various sources, in particular theOverseas Development Administration
(ODA) of the UK government, now known as the Department for
International Development (DFID), and also fromUSAID, among others.
There were a few ODA scientists at NVRC still working on ECF and ITM,
notably Alan Young and Tom Dolan. But there was a degree of scepti-
cism, and perhaps scientiﬁc arrogance, that was associated with ILRAD
during its early years of existence. There was an impression among
some scientists at ILRAD that furthering ITM immunisation was not
science, and this view continued to bewidely prevalent until themerger
with ILCA and the birth of ILRI in 1995. Therewas alsowidespread belief
among ILRAD scientists that a subunit ECF vaccine was just around the
corner, and this inﬂuenced the Directors of Veterinary Services of the
region (especially in Kenya), which in turn gave rise to the lukewarmsupport of the ITM. Nevertheless there was a small group of scientists
at ILRAD who did venture into the ﬁeld, and undertook parasite isolation
and ITM immunisation studies at three government ranches located in
the coastal region of Kenya (Morzaria, 1989) [31].
Then came the new institute ILRI in January 1995, with a newDirector
General, and a revived discomfort of the past unfulﬁlled promises of
vaccines against trypanosomiasis and ECF vaccines “within ﬁve years”.
These changes certainly turned the tide a little for ITM, resulting in several
new engagements within the region, and also paved the way for a
renewed link with FAO and the ensuing request in 1996 for ILRI to
prepare a commercial scale MC stabilate.
4.3. The concern about live vaccines and spread of vaccine strains to new
areas
Several concerns had been raised about thewider use of the ITMMC
vaccine. These mostly centred on the awareness that the use of a
live vaccine meant that vaccinated animals become “carriers” of the
T. parva strains being used in the vaccine, and that they then provide a
source of these strains to ticks in the ﬁeld, and as a result have the
potential to infect co-grazing non-vaccinated animals with these
strains. These concerns, and their implications in the light of subsequent
understanding, have been extensively reviewed by Declan McKeever
[32,33]. Over many years became a central obstacle to the acceptance
of the MC as an option to be deployed in different countries of the
region. This led to extreme caution on the part of Directors of Veterinary
Services and other government ofﬁcials unfamiliar with the science
behind the vaccine, who did not want to be seen to be condoning
the introduction of “foreign” parasites into a new area. Part of this
was because many new stabilates isolated were given a name, usually
referring to the geographical area or region in which it had ﬁrst been
identiﬁed. Interestingly, even Kenya was opposed to the use of the MC
as it contained a buffalo stock! The confusion was further deepened
by the scientists themselves, inadvertently fuelling the debate in publi-
cations and meetings.
The NVRC in Kenya searched for a master stock without buffalo ori-
gin parasites. The isolation of T. parva Marikebuni was believed to be
such a strain [25]. For the next 20 years Kenya invested heavily in the
development of Marikebuni as the vaccine of choice. ODA support was
intended to lead to the commercialisation of Marikebuni and a MoU
was signed with Cooper Kenya, but this partnership was not successful.
It is now generally believed that the risk of adverse reactions from
the use of MC and the resultant introduction of its strains is of no signif-
icant consequence, as there is a substantial degree of sexual recombina-
tion among T. parva strains in the ﬁeld, resulting in huge parasite
diversity (Oura et al., 2007 [34]; Patel et al., 2007 [35] However, there
are still people who ask the question whether strain variation is impor-
tant and whether use of the MC as a standard regional approach can
lead to the introduction of strains into countries where they do not
currently exist. The evidence has never been good enough to silence
the doubters. As a result, current initiatives coordinated by GALVmed
in Rwanda and the Democratic Republic of Congo (DRC), for example,
are taking a cautious and pragmatic approach by testing MC under
controlled trials in newmarkets prior to requesting the right to import.
Importantly, it is known thatMC has been used in certain of these coun-
tries in the past, seemingly without adverse effects.
4.4. The reorientation of the ECF vaccine research agenda
The success of the UNDP-sponsored FAO project at Muguga had a
signiﬁcant impact on the conﬁdence and hope of parasite immunolo-
gists, demonstrating proof of principle that cattle could be exposed to
Theileria strains and develop a strong and long-lasting immunity,
boosted by new challenge from infected ticks in the ﬁeld. Although
the mechanism of immunity was still unknown in 1977, and the role
of cytotoxic t-cells was not yet discovered, an air of conﬁdence had
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wave of conﬁdence coincided with the establishment of ILRAD, with
its highly sophisticated facilities, its staff of highly qualiﬁed scientists
recruited from different corners of the world, and its speciﬁc mandate
to develop vaccines. The result was that the technicalities and mecha-
nisms for further deployment of ITM was in effect side-lined for the
next 20 years. These became the wilderness years of ITM and the MC.
It certainly was not forgotten, as the ensuing 20 years sawmuch discus-
sion on the differing epidemiology of ECF under different production
systems, in different breeds and at different latitudes, but virtually
nothing was done to move ITM to the next level and have it deployed
as a commercial product in the ﬁeld. ILRAD, and its successor ILRI (as
it became from 1995), moved into the ﬁeld of developing new recombi-
nant vaccines, and of following the trend at the time of mapping the
Theileria genome [35,36,37].
As well as looking to new generation vaccines, ILRAD and ILRI used
these years to develop awide variety ofmolecular tools to better under-
stand and characterise the different T. parva parasites being investigated
as potential vaccine candidates. As far as ITM was concerned, these
molecular techniques brought extremely valuable tools to its character-
isation and use. These included: the ability to establish quality control of
the ITM vaccines such as the MC; the ability to monitor for possible
vaccine breakthroughs and breakdowns; and the capacity to assess
the impact of introducing new parasite strains into the vaccine on its
long-term efﬁcacy. The work focused on two main categories of tools;
serological (such as schizont - speciﬁc monoclonal antibodies [38])
and DNA-based (various genome-wide polymorphic markers, southern
blotting, polymerase chain reaction (PCR) and single strand conforma-
tion polymorphism) [39].
4.5. The years of regional dialogues
The successes in Kenya, combined with a continued interest from
FAO, a new ﬁeld epidemiology and impact assessment initiative by
ILRAD, and an increasing engagement of AU-IBAR, triggered a set of
valuable regional dialogues on ECF and its control over a period of
15 years.
The ﬁrstworkshop in this serieswas held in Nairobi in October 1984,
when participants provided updates on theileriosis in the countries of
the region, reports on immunization trials, and papers expanding on
elements of immunization [40]. The second workshop, held in Nairobi
in September 1985, emphasised data collection and handling as well
as analyses of productivity in relation to immunization [41]. This work-
shop introduced participants to practical data handling and computer
use. The third workshop was originally planned for November 1987
but was postponed due to uncertainty about the funding of some of
the FAO tick and tick-borne disease control projects. The workshop
was eventually held in Lilongwe, Malawi, in September 1988, with
considerable support from the Malawi Government.
The Lilongwe meeting had an important spin-off. It provided an
opportunity for a sharing of information and understanding on
theileriosis throughout the eastern and southern African region,
and it became apparent that there were signiﬁcant differences in
the disease epidemiology between the eastern and southern regions.
Whether this was real or due to the diversity of studies that had been
undertaken or interpretations thereof was not entirely clear. Whatever
the source, it stimulated a discussion, and the Lilongwe meeting was
where the only text book on the epidemiology and control of ECF was
conceived. The preface to “The Epidemiology of Theileriosis in Africa”
[7] comments: “during discussions after the day's session, Alan Young
suggested that the three of us (Andy Norval, Brian Perry and Alan) attempt
to prepare a review article on the epidemiology of theileriosis throughout
its distribution in Africa, with the objective of rationalising the differences
in patterns of the disease, particularly those between eastern and southern
Africa. During early gestation, it became clear that a review article would
not accommodate this objective, and the project quickly grew into abook”. The book was published by Academic Press, and became a key
reference point for all working on the control of ECF.
Then in September 1989 FAO called an Expert Consultation at FAO
headquarters in Rome on the revision of strategies for the control of
ticks and tick-borne diseases, the proceedings of which were published
in Parassitologia (a journal of the Institute of Parasitology of theUniversity
of Rome; Parassitologia, 1990). Next it was the turn of Uganda to host a
regional meeting in September 1991 (Dolan, 1993 [42]), which was
again organised jointly by OAU/IBAR), FAO and ILRAD. The workshop
was timed to coincide with the annual review meeting of the FAO
national and regional projects, and the Government of Uganda convened
an additional supplementary meeting to address the speciﬁc tick and
tick-borne disease problems in Uganda.
There was then a gap in the regional meetings until March 1996,
when a meeting focussing on the epidemiology of tick-borne diseases
across the region was held in Harare, organised by FAO in association
with the new emerging institute ILRI [43]. This was followed a year
later in March 1997 by a workshop at ILRI which was again jointly
organised by OAU/IBAR, FAO and ILRI [45]. The workshop focussed on
the deployment of live ECF vaccines and the problems associated with
their delivery.
These meetings played both positive and negative roles. On the posi-
tive side, they provided a very valuable opportunity to share studies and
research in what became a “club” atmosphere, and provide the opportu-
nity for younger scientists to both present their results and to discuss
informally with their peers from other countries and institutions. On the
negative side, they were at times seen as a hub for conspiracy theories,
and were termed “disruptive” by some due to the tabling of sometimes
damaging suggestions and concerns on the role and application of ITM.
4.6. The devolution of ﬁeld studies
In part as a result of the earlier successes in Kenya, and in part from
the regional dialogues, there was a growing interest among scientists
and other donor organisations to explore ECF immunisation in other
countries of the region. Until the collapse of the EAC in 1977, a joint
FAO/UNDP project was operating in Tanzania, and following a study of
the use of the MC in experimental cattle held at Pugu near Dar es
Salaam, recommended its routine use on a large scale in the country
[27]. However the collapse of the EAC brought the UNDP funding to an
end. The Danish International Development Agency (DANIDA) then
came in 1980 with support for a series of projects on ECF control in
Malawi, Zambia and Zimbabwe, and eventually, in 1990, brought
Tanzania into this programme.
In Zambia, a Belgian animal disease control project started using the
ITM method of immunisation against ECF, but using a T. parva stock
isolated from Zambia (the Katete isolate), rather than using the MC
(Lynen et al., 1993) [46]. This was extremely successful, and Zambia
has continued to use this stock, with the vaccine being prepared at the
Centre for Ticks and Tick-borne Diseases (CTTBD) in Malawi. Interest-
ingly, Lieve Lynen thenmoved to Tanzania, where she continued to pio-
neer the use of ITM, but using theMC, initially supplied to her project by
the VPC inMalawi (which later became the CTTBD), but after 1996 using
the FAO 1 batch produced at ILRI.
Malawi started using the MC in 1984 following extensive ﬁeld trials
showing its efﬁcacy under Malawi conditions. This continues, with
vaccine being sourced from CTTBD.
Various trials were also carried out at different intensities in other
countries, notably Rwanda, Uganda and Zimbabwe, reported in Morzaria
and Williamson, 1999) [45].
4.7. The production of commercial scale batches of MC vaccine by ILRI
At the birth of ILRI in 1995 there was a strong awareness that on the
onehand the new long-promised recombinant vaccineswere still a long
way off, and on the other that the much discussed ITM vaccine was still
6 The Economist, Aid Policy, October 31st 2002.
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Fig. 1. The complexities of preparing a Muguga cocktail (MC) stabilate. From Morzaria et al. (1997) [44].
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prepare a commercial scale batch of the MC. Julio de Castro was the
incoming Senior Animal Health Ofﬁcer at FAOheadquarterswith partic-
ular responsibility for tick-borne disease control, and was reportedly
concerned that although FAO had invested so much over many years
in ITM, no workable product had emerged. While he realised that
some of the southern Africa countries, and the donors supporting their
work, wanted their own stocks and strains for immunisation, which
had become a substantial political force at the time, he felt that it was
high time for the MC to be more widely available; countries could
make their own decisions on its use. He made available a Technical
Cooperation Programme – TCP project for about $250,000. There was
a shortage of immunising stabilates in the region due to increasing
demand in the different countries of the region, andbecause the Vaccine
Production Centre (VPC) in Malawi (see section 4.10 below) was not
functioning at full capacity, ILRI agreed to prepare the vaccine stabilate
and send it to Malawi. At the time of the request, it was considered
that there was no other institution in the region with the capacity to
produce the MC.
The key players at ILRI responsible for preparing the stabilate were
Paul Spooner, supported by Subhash Morzaria, Tony Musoke and
Stephen Mwaura. Certain modiﬁcations from the original protocol for
MC preparation were introduced, some of which were adopted as part
of the standard ILRI procedure for stabilate preparation. Other amend-
ments were also introduced to fulﬁl the requirements of the Ofﬁce Inter-
national des Epizooties (OlE) recommended standards for biological
products (OlE 1996) [47], and the proposed new standards that had
been set by the Standards Committee, representing the OAU, FAO and
ILRI. A protocol for the production of MC was published in a meeting
proceedings (Morzaria et al., 1997) [44] (see Fig. 1), and this protocol
has recently been brought up to date by Patel et al. (2016) [48].
The ﬁrst batch produced by ILRI was designated FAO 1, comprising
about 250,000 doses, and it was sent to VPC in Malawi (VPC changed
its name in 2001 to Centre for Tick and Tick borne Diseases (CTTBD)).
The intentionwas that funds from the sale of vaccinewould be reinvested
in newproduction capacity at VPC in order to create a sustainable vaccine
production centre for the region, but it appears that did not happen.Then in 2007 ILRI was called on yet again to produce another large
batch of MC. This time the request came from the AU/IBAR, and again
driven by the lack of availability of MC, the decline in effectiveness of
the VPC, and a continuing demand from the countries of the region.
The preparation of the batch was undertaken by Paul Spooner, Steve
Mwaura and Phil Toye, and the batchwas designated as ILRI 08. Perhaps
surprisingly, it was kept at ILRI in Nairobi and distributed from there to
Tanzania (the majority), Kenya, Uganda and Malawi, among other
distributor demands.
4.8. The DFID drive towards a poverty reduction agenda
In 1997, the incoming Labour Government of the UK established a
newDepartment for International Development (DFID),with responsibil-
ity for the £4 billion aid budget and other aspects of UK development
policy, led by Clare Short. In the subsequent eight years, the new Depart-
ment established a reputation for itself, and for the UK Government, as a
leader in development thinking and practice. DFID was described by The
Economist6 as “a model for other rich countries.” What has this got to do
with ECF vaccine development?
The newminister Clare Short changed the approach to international
development assistance in the White Paper presented to parliament in
the UK.7 In her introductory comments, she said: “The White Paper is
ﬁrst and most importantly about the greatest single challenge which the
world faces – eliminating poverty. It is about ensuring the poorest people in
the world beneﬁt as we move towards a new global society”. Of particular
relevance to the role of livestock and livestock disease control was the
section on sustainable livelihoods, where six elements were highlighted:
pro-poor economic growth; efﬁcient and well-regulated markets; access
of poor people to land, resources and markets; good governance and
the realisation of human rights; prevention and resolution of conﬂict;
and the removal of gender discrimination.
Working for DFID at the timewith the Livestock &Wildlife Advisory
Group in the Rural Livelihoods Department, and with responsibility for
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on thewind of change in DFID, and applied the newprinciples to animal
disease research. On 22ndNovember 2000 Sarahwrote to Brian Perry at
ILRI saying: “DFID is re-thinking the way in which we provide support to
animal health research. This will involve a re-orientation of the research
programme to focus diseases that are important to poor people, rather
than diseases of production (the two may or may not be the same). To
kick start the process we need to commission a study to identify and
prioritise those disease research issues that are likely to be important to
poor livestock keepers. Would you be interested/able/willing to do the
study for DFID?”
The answer was of course yes, and this initiated a process which
brought together scientists and opinion leaders in Africa, Asia, Europe
and North America, and which was to deliver one of the highest impact
products of ILRI's epidemiology group (Perry et al., 2002) [49]. The
Inter-Agency Development Group (IADG) of international donors to
livestock research and development, of which DFID was a leading
member, had just been formed to bring greater coordination between
its membership in the funding of livestock research.8 As part of this
process, it sought to better deﬁne the animal health research priorities,
and DFID proposed that these be placed in the context of poverty
reduction.9 This required ﬁrst deﬁning poverty and the association with
livestock, and then quantifying the association, a processwhich continues
to be reﬁned [50].
This study has had a lasting impact on animal health research priori-
ties for development, and is still the most cited reference in this context.
In addition, it set the stage for measuring the association of poverty and
livestock, and for applying greater emphasis to the impacts that research
in animal healthhas onprocesses of poverty reduction, rather than simply
on national agricultural development. Other research and development
sponsors were also inﬂuenced.
There were several important implications for ECF and the ITM
immunisation. Firstly, even in the region in which the disease occurs,
ECF was ranked as 11th on the priority scale, while at the global level
it ranked as 35th [49]. There are many factors behind this. The low
ranking was due to the fact that it occurs in just one species, cattle, and
although that species ranks highly in eastern, central and southern
Africa as important to the poor, it is usually the indigenous zebu
and sanga breeds that play the most important role in poor house-
holds in mixed agro-pastoral systems, rather than the more suscep-
tible European breeds, in which ECF has a high impact. The
importance of ECF was thus characterised as constraining the pro-
cesses of intensiﬁcation by smallholders, rather than affecting the
fundamental assets of poor livestock keepers. Importantly, however,
the opportunity for delivery of ITM was identiﬁed as one of the “low
hanging apples”, attainable within a short time frame and at a low to
medium cost.
A follow-up meeting of the IADG was held in Paris in April 2002, at
which it was decided to explore how the private sector might be
encouraged to tackle some of the so-called low hanging fruit technolo-
gies. A month later, DFID received the ‘go-ahead’ from Claire Short for
the design phase of a would-be Private Sector Initiative (called the
Rural Enterprise Technology Facility, RETF). DFID commissioned the
Cambridge Economic Policy Group, who developed what they initially
called a draft Global Animal Health Alliance, but which evolved, in
April 2003, to become the Public Private Partnerships on Livestock
Vaccines for the Poor. This recognised that there was a global failure in
markets to generate and deliver animal health technologies in these
countries, and particularly for targeting the poor. The study discussed
the concept with various actors in the private sector and reported that
major pharmaceutical companies such as Merial, Intervet and Pﬁzer
would bewilling to participate in an alliance and to contribute expertise8 https://www.donorplatform.org/livestock-development/major-events.
9 http://r4d.dﬁd.gov.uk/PDF/Outputs/RLAHAnnRep_2001-2002.pdf.and IPR to the development of speciﬁc products, subject to appropriate
funding and management structures being put in place. The onus was
put on the donors to reach agreement on the concept, and to identify
appropriate funding and management arrangements. This prompted
DFID to explore various options, and it went on to facilitate the
establishment of the Global Alliance for Livestock Vaccines (GALV) in
2004 with an appropriate legal and institutional framework and its
ﬁrst business plan. It was envisaged that GALV would work in a similar
way to the GAVI Alliance,10 an organisation with a human vaccine
agenda.4.9. The emergence of GALVmed
DFID provided a £300,000 grant in an inception phase for GALV as
it picked up the public-private partnership mantle on animal health
technology reﬁnement and delivery, including the ITM vaccine for
ECF.11 Then GALV became GALVmed12 (Global Alliance for Livestock
Veterinary Medicines), the change of name reportedly reﬂected the
recognition by the management and board of GALVmed that although
vaccines were important, the development of other types of veterinary
medicines, including drugs, would also be relevant to their agenda. As
seed funding from October 2004 to October 2008, DFID injected some
£2.6 million to get the organisation off the ground. During this period,
considerable time and effort was invested in fund raising, and the organi-
sation took on Steve Sloan for this task, under former Merial scientist
Xavier Fargetton as CEO.
This fundraising initiative was very successful, and led to a new
Phase 1 of GALVmed from September 2009 to September 2012 of
£14.8 million, of which the Bill and Melinda Gates Foundation (BMGF)
contributed 80%, and DFID 20%.
Following this, DFID and BMGF decided to jointly fund a second
phase of GALVmed from July 2012 to June 2017, to which they jointly
committed to provide over £31.2 million (DFID contributing 20% and
BMGF 80%). GALVmed has also been able to raise some £25 million
from BMGF, DFID, the EU and BBSRC for a variety of other (non-ECF)
programmes.
Since 2008 GALVmed has helped facilitate the improved functionality
of the CTTBD in Lilongwe,Malawi, the successor of theVPC, through train-
ing, re-equipping and technical support (GALVmed 2015) [51]. CTTBD
won the tender to produce the MC following a tendering process by
AU-IBAR-chaired ECF regional task force, comprising government repre-
sentatives of the four countries currently using the ECF MC vaccine
(Malawi, Kenya, Tanzania and Uganda), GALVmed, ILRI and Pan-African
Veterinary Vaccine Centre (PANVAC).
From the ECF live vaccine point of view, GALVmed has stepped
into the breech and developed amost impressive public private part-
nership. It has been helped by the solid and continuing support of
DFID, which contributes some 15% of the funding of GALVmed's
wide range of activities (and which has recently indicated its intent
to continue its support), and by the very successful fund raising, in
particular with the BMGF, who have also placed both vaccine deploy-
ment and ECF high on its priorities. GALVmed currently plays the role
of facilitator and broker for sustainable ITM production and deploy-
ment (using the term ECF-ITM to describe the product), seeking to
end the wilderness years of ITM andMC. While it is carefully backing
the opening up of new ECF vaccine delivery initiatives in Rwanda,
Burundi, Democratic Republic of Congo (DRC), Uganda and South
Sudan, it sees itself being replaced as broker of ITM production with-
in the next two to ﬁve years, with the technical support being pro-
vided by a private enterprise.10 http://www.gavi.org/.
11 http://www.galvmed.org/en/livestock-and-diseases/livestock-diseases/east-coast-
fever/.
12 https://www.galvmed.org/en/.
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Diseases (CTTBD), Malawi
Towards the end of the 1970s, construction of a facility for ECF vaccine
production capacity was set up outside Lilongwe in Malawi under the aus-
pices of the AfricanUnion. The Tick-borneDiseases Vaccine Production Cen-
tre (VPC), managed by Fred Musisi, included the capacity to produce other
TBD vaccines for babesiosis and anaplasmosis. The government of Malawi
set up the VPC with technical assistance of FAO and ﬁnancial co-operation
of various donors, principally the governments of Denmark and the
Netherlands, and UNDP. The objectiveswere to look into the available tech-
nologies for immunisation against TBDs and to subsequently evolveproduc-
tion systems that would meet the minimum standards of registerable
vaccines under Good Manufacturing Practices (GMP). In his report of
1997, Chizonda (1999) [52] wrote that shortly after its inauguration, the
VPC encountered several problems, including the loss of four of its ﬁve ex-
ternal technical assistance staff, and nearly half of its national technical
support staff. Vaccine production was then suspended indeﬁnitely.
In 1998 there was an initiative to resuscitate the vaccine facility in
Malawi with support for ﬁve years by two donors (Netherlands and
Belgium), renaming the facility in 2001 as the Centre for Tick and Tick
borne Diseases. The main objective of the Centre was to produce live
vaccines against ECF, provide training in epidemiology and other areas
of TBD control, backstop ﬁeld projects involved in the integrated control
of TBDs, andundertake research. Itwas decided that the Centrewould not
produce vaccines against Babesia and Anaplasma, as it had previously.
There has been substantial debate on how andwhere to best provide
the countries of the region with the ITM technology for ECF. The only
places where theMC had been produced, until recently, was at Muguga
in the 1970s, and at ILRI in 1996 and 2007. Kenyawas, frommany points
of view, the logical place to produceMC, but this argument was compli-
cated by the fact that not all countries of the regionwanted to useMC. In
fact many were quite adamantly opposed, during the era of a lack of
understanding of the nature of introducing these Kenya-origin stocks
into other countries.
Research at ILRAD, ILRI and other institutions in the countries of the
region had successfully identiﬁed a variety of T. parva stocks, some of
which were the products of research projects, and some of which
became considered as potential candidate vaccine strains, particularly
in countries whose authorities would not accept the importation of
the MC. Examples were T. parva Katete and T. parva Chitongo in
Zambia, and T. parva Boleni in Zimbabwe.
After the 2007 production of the MC (ILRI 08) at ILRI in Nairobi, there
was anextendeddebate as tohowsustainability inbothproductionanddis-
tributionof the ITMtechnologycouldbeestablished. Themainpolitical force
at the timewas the groupofDirectors of Veterinary Services of the countries
with the strongest demand for the vaccine, namelyKenya, Tanzania,Malawi
and Zambia. Through the leadership and facilitation of AU/IBAR, a commit-
tee involving this groupwas established,which also includedGALVmedand
the Pan-AfricanVeterinaryVaccineCentre PANVAC. This committee opened
a tender for both themanufacture anddistribution of the vaccine. The views
at the time were many. Some believed that vaccine should continue to be
produced at ILRI, where the track record and all the facilities existed for
the complexities of stabilate production. There were also strong feelings
against ILRI producing the vaccine, both from some of the countries in-
volved, and from ILRI itself, which is a research institute and not Good
Manufacturing Practices (GMP) compatible for vaccine production.
In the end the tender formanufacturewent to CTTBD. GALVmedhad
already committed to prioritising ECF control in its portfolio, and
stepped in with signiﬁcant investment to re-equip the laboratories
during the period 2008–2014. Despite CTTBD winning the tender for
ITM manufacture, there was to be a wait of six years before the
revamped centre was launched (in December 201413). This was report-13 https://cttbdlaunch.wordpress.com/.edly carefully planned to avoid yet another launch of the facility before
all equipment and personnelwere in place, and theﬁrst batch of vaccine
produced and available.
GALVmed continues to provide support to CTTBD in various ways,
including assistance to management, to its cash ﬂow challenges associat-
ed with unpredictable vaccine sales to different players in the region, and
to vaccine production and sales. Importantly it also provides consultancy
services to CTTBD; ironically TonyMusoke, veteran of EAVRO at Muguga,
is helpingwith the further reﬁnement of facilities in Lilongwe, and is back
at the front line involved in supporting new ITM initiatives in
Rwanda, Burundi, Democratic Republic of Congo, Uganda, Mozambique
and South Sudan.
CTTBDhas a steering committeewhichmeets regularly and oversees
vaccine batch release. It also had a board, made up of the Directors of
Veterinary Services from the purchasing countries meeting annually,
until recently under the chairmanship of Musa Fanikiso, a former Direc-
tor in Botswana. A new board has now been appointed, chaired by
Tumusiime Rhoda Peace, Commissioner for Rural Economy andAgricul-
ture at the African Union.
The challenge remains of moving a technology for which there
appears to be a strong but variable demand in the region, and for which
livestock producers are generally prepared to pay, into a sustainable
private enterprise. GALVmed has just signed a contract with a private
sector company to explore this option further,with the companybringing
in management and technical contributions to quality assurance, eventu-
ally moving towards proﬁt sharing.
CTTBD's main product is currently the MC ECF vaccine for the coun-
tries of eastern Africa (Tanzania, Uganda, and Kenya) and Malawi.14 In
addition, for the past decade or so, CTTBD has been producing two
subtypes of monovalent ECF vaccines for southern (Chitongo strain) and
eastern Zambia (Katete strain), with the latest batches having been
delivered in April 2016. All these vaccines are produced with the
accompanying diluent as a package for the end use. ITM vaccine
sales are now in excess of 1.5 million doses, with uptake (in order
of size ofmarket) in Tanzania, Zambia, Kenya andUganda. Theseﬁgures
reﬂect sales from ILRI 08, MCL 01 and Zambia batches only, and exclude
sales from earlier batches.
ECF-ITMvaccines are currently packaged in 0.5ml straws containing
40 doses which may not be cost effective to smallholder farmers with
1–5 cattle. The use of a complete straw's doses is sometimes difﬁcult to
achieve, and vaccinators are left with a logistical challenge of organising
a total of 40 animals.
5. The Muguga Cocktail; is it a success, and if so, what has been the
impact?
5.1. The indicators and views of success
The original ITM live vaccine technology was developed about
40 years ago. Has it been a success? Clearly many people think it has,
and it is a technology that is now out in the ﬁeld and being used, and
its wider distribution is being supported by governments, international
donors and institutions. A few indicators are presented and discussed
below.
• There is no other vaccine to prevent ECF despite over 40 years of
heavy investment and research. While this is hardly an indicator of
success, the reality is that no other vaccine has yet been developed
to protect against ECF in theﬁeld. At the time that the ability to protect
cattle with this live vaccine was ﬁrst demonstrated, work started at
ILRAD, then continued at ILRI, to develop a new recombinant vaccine.
Some partial successwas achievedwith a sporozoite vaccine, based on
the surface protein p67 (Musoke et al., 2005) [53], giving a reduction in
the severity of disease in immunised cattle, but there was inadequate14 http://www.cttbd.org/vaccines.
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continues at ILRI on a novel recombinant vaccine with support from
the Bill and Melinda Gates Foundation (BMGF) and others at ILRI15,16
• The MC immunisation provides long-term, some consider life-long,
immunity in the ﬁeld.
• Over 1.5 million doses of MC have reportedly been administered in
approximately eleven countries of eastern and southern Africa. The
breakdown of this ﬁgure by country, production system and cattle
type is not available.
• The greatest impact appears to have been in Tanzania, in part due to the
commitment of the group championing its use in and around Arusha,
and in part due to the unique demand in the pastoralist communities
in northern Tanzania and southern Kenya. These have been docu-
mented extensively by Di Giulio et al. (2009) [31].
• The MC vaccine is only registered in Malawi. The MC vaccine has
been registered in Kenya and Tanzania, but these registrations
have lapsed. Nevertheless it is used in both of those countries,
and in Uganda, through importation under special permit. The
MC is also being used in DRC, South Sudan, Rwanda, and Burundi.
The technology of ITM is also used in Zambia, using the Katete
and Chitongo stocks of T. parva, not the MC. ITM technology has
also been deployed on a commercial basis in Zimbabwe, using the
Boleni stock of T. parva and without the use of tetracycline.
• The impact on the establishment of ILRAD and the ECF vaccine research
programme. What momentum did the successes of the FAO project at
EAVRO, Muguga, have on the establishment of ILRAD? There was
certainly an overlap in the timing, with the CGIAR launched in 1971,
the livestock subcommittee a year later, concurrent with the ﬁrst dem-
onstration of protectionwith theMC, and the initial attempt to establish
ILRAD at EAVRO. One can speculate that the EAVRO successmight have
inspired the creation of ILRAD. Former Director General of ILRAD Ross
Gray argues that trypansomiasis became the primary objective behind
ILRAD very early in the CGIAR's project, not tick borne diseases, and in
the review carried out ﬁve years after ILRAD's establishment, equal
weight appears to be given to both diseases, with the common theme
of immunological approaches to control them (TAC, 1981) [54].
• The impact on the understanding of the bovine immune system. The
successes of the FAO team at EAVRO, and the establishment of ILRI
with itsmandate of vaccine development stimulated a new and intense
scrutiny of the bovine immune responses to different parasites, and is
perhaps well illustrated by Ivan Morrison's book [55].
• The establishment of a functional international Public-Private
Partnership to address themarket failure of animal health technologies
for the livestock enterprises of the poor. This must be one of the most
signiﬁcant indirect products of the ITM technology, and while this
narrative cannot comment on the overall performance of GALVmed,
there is no doubt that it is now ﬁrmly set on the path of ensuring that
ECF-ITM is produced sustainably, and is effectively delivered. There
can be few public private partnerships targeted at animal health
technologies which combine a global funding agency at the scale of
BMGF, and an international development ofﬁce of amajor industrialised
country (DFID), and it appears that GALVmed is starting to achieve the
kinds of impacts these partners were seeking. GALVmed itself does not
rank ECF ITMas its greatest success in vaccine delivery, a positionwhich
it currently gives to its vaccine programme for Newcastle Disease of
poultry, in which the programme GALVmed has engaged several pri-
vate enterprise manufacturers and deliverers.
• The capacity building of African scientists. There is no doubt that the
funding and training opportunities presented by the work of NVRC,
ILRAD and ILRI, as well as research institutions in Tanzania, Uganda,
Zambia, Malawi and Zimbabwe played a signiﬁcant role of capacity
building of individual scientists across the region. It is less clear that it15 https://ilvac.net/2014/02/11/new-gates-funded-vaccine-project-tackles-east-coast-
fever-in-cattle-in-africa/.
16 http://www.ilri.org/node/33164.had a substantial impact on institutional capacity, with the clear excep-
tion of ILRAD and ILRI which attracted the cream of aspiring scientists,
arguably at the expense of their national institutions.
5.2. The qualiﬁers of success
In addition to several clear indicators of success, and of both direct
and indirect impacts of the development and deployment of the MC,
there are certain qualiﬁers of these successes. These apply to the tech-
nology itself, and to the adoption process. These are presented below.
• The manufacture of a commercial scale batch of the MC stabilate is a
complex, costly and time consumingprocess. The facilities and technical
support of ILRI in producing FAO 1, FAO 2 and ILRI 08 absorbed the pro-
hibitively high cost associated with the production of these stabilates.
Since then, in the production of theMCL 01 stabilate at CTTBD, ﬁnancial
and technical consultancy support has been essential, and even with
that various technical challenges affecting product quality have been
experienced. The sourcing of disease-free cattle in the relatively small
country of Malawi is but one of those challenges.
• To produce one million doses of vaccine requires 130 cattle that have
not previously been exposed to the disease, 500 rabbits and at least
600,000 ticks. The entire process of making the batch takes up to
18 months. This raises some ethical issues. The vaccine release has
now been amended to reduce the number of cattle used and to shorten
the release. It was recognised that three reﬁnements of the dilutions
were not needed to quantify the effective dose, so two serial dilution
steps were taken out. This shortens the production time and uses
fewer cattle (with a beneﬁcial ethical impact as well as a reduction in
production costs).
• There remains no good correlate of the potency of emerging stabilates,
which need to be evaluated empirically through assessment of
the number of infected acini in each infected tick batch. This is
both inadequate in reﬂecting potency, and is extremely time consuming
and labour intensive.
• The registration enigma. It has been extremely difﬁcult to secure and
maintain registration of the MC. The MC has been registered in both
Kenya and Tanzania, but these registrations have lapsed. GALVmed
have contributed to the process of development of registration dossiers,
but the major challenge is an insistence by the authorities on GMP
capacity for vaccines. There are guidelines on GMP for veterinary
vaccines, but it seems that these are interpreted by each country.
Currently neither ILRI nor CTTBD meet GMP standards for vaccines. It
is considered by some that this compliance failure is in part a reﬂection
on the misalignments between the different Directorates of Veterinary
Services and the relevant local regulatory body in the countries
concerned.
• The complexity of strains and stocks, and the failure to silence the
doubters. There is no doubt that the 1996 initiative by FAO to request
and fund the ﬁrst full commercial scale batch of theMChelped substan-
tially in gaining acceptance of the wide use of these stabilates across
country borders. This acceptance was deepened by the apparent suc-
cesses of MC in reducing ECF mortality in northern Tanzania.
However, the reluctance by Directors of Veterinary Services and other
decision makers to approve the manufacture and deployment of the
MC severely hampered its impact, and continues to do so to a degree.
• The necessity of a rigorous cold chain. The product requires a well-
managed cold chain and careful handling to deliver and administer
carefully and correctly so that it is has themaximum chance of full efﬁ-
cacy. This has generally required coordination by trained veterinarians
on farms and ranches. This is not a straight forward process, and
requires infrastructure, training and coordination. Responding to the
need for greater attention to MC delivery, there is a USAID-supported
project in Tanzania managed by ILRI which aims to widen the distribu-
tor network and provide training to different private enterprises.
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work that adequately meets the demand of the MC distribution
aspirations. The artiﬁcial insemination (AI) programme provides a
basis for this distribution in Kenya, but it is far less developed in
Tanzania.
• The MC successes in northern Tanzania have not always been straight
forward. Prior to 1998 there was an unacceptably high level of clinical
reactors in the Kilimanjaro region, and thiswas addressed by increasing
the concentration of oxytetracycline, as described above.
• Beyond the technical challenges encountered in the early stages of MC
delivery in Tanzania, the mostly positive impacts were not straight
forward in development terms. Homewood et al. (2006) [56] showed
that although the ITM vaccine has an overwhelming impact on survival
through protecting against fatal ECF, reducing calf mortality from over
20% to around 2%, the distribution of those impacts on livelihoods of
cattle owners and their families were not uniform. They showed that
when the vaccinewas provided on a commercial basis, poorer livestock
keeping households vaccinated a smaller proportion of their calves and
immature animals (30–34%) compared to thewealthier households (up
to 90%). Part of thiswas due to the cost of the vaccine (US$ 6–10), and in
part due to the vaccine pack-size issue (referred to earlier). With the
vaccine kept in straws in liquid nitrogen, and diluted in the ﬁeld for
immediate use into about 40 doses, only larger scale operators could
gather the necessary numbers of calves for vaccination at one place
and time. This discriminated against the smaller scale producers, who
alsoweremore prone to logistical problems of assembling their animals
in the right place and at the right time.
• Public or private good? In all disease control interventions, particularly
those targeting speciﬁc diseases in low and middle income countries,
and particularly in poor rural areas of such countries, the question of
ﬁnancial responsibility emerges (see Kirsten et al., 2009) [57]. As an
endemic disease and one that is not affecting national or international
trade, ECF control and prevention is generally considered a private
good, and this is the position adopted by CTTBD and GALVmed. There
are many component costs of the MC, and it emerges at something
between $6–10 per dose. This is substantially more expensive
than say the vaccine against foot-and-mouth disease. Nevertheless,
in Kenya there is, at least in theory, a substantial market for the MC
throughout the country to serve the growing livestock enterprises in
different production systems. However, in reality there appears to
be a dramatic difference in uptake by production system and agro-
ecology. In some parts of Kenya, particularly the highland regions in
which smallholder dairy is widespread, supplying the large part of
Kenya's milk demand, there has been a conﬂict of interest with the
business enterprises of private agro-pharma suppliers. Many such
private distributors feel that the long term immunity associated with
a vaccine will interfere with their established markets for acaricides
and anti-theilerial drugs (such as parvaquone and buparvaquone),
and reduce their proﬁt margins on these products. There were reports
of companies which put in bids to take over and monopolise the distri-
bution of MC, but in reality were not planning to distribute any vaccine
as they feared it would reduce the lucrativemarket for acaricides. There
have been several reports of companies and veterinarians actively
discouraging farmers from using the MC. As a result, a code of practice
has been set up by the Directors of Veterinary Services; the Directorate
of Veterinary Services has authorised only certain accredited distribu-
tors to deliver the MC. But the low uptake of MC is not just based on
the business aspirations of the agro-pharma companies. As Kenya's
smallholder dairy system is characterised by 1–3 cows kept in zero
grazing stalls, not only is their risk of acquiring ECF lowerwith very little
pasture grazing, but also the use of knap-sack spray application of acar-
icides regularly by the farmer is both easy and cost effective. In the dryer
pastoralist regions of Kenya there is also a substantial demand forMC, as
there is in northern Tanzania, and it is in these areas, particularly
Kajiado and Narok where the greatest demand for the MC lies. This ap-
pears to be for various reasons. Froma logistical point of view, it is easierto deliverMC to larger herds, given the 40 doses emerging fromany one
straw of stabilate. And secondly it would appear that the larger agro-
pharma distributors are less concerned about their acaricide markets
in these areas, likely linked to the logistical challenges of administering
acaricides regularly to large herd without dip tank facilities. Indeed a
complex matrix of different business interests.
• The pack-size enigma. The irony is that the current format of the tech-
nology biases against a major market segment, not only in Kenya but
throughout the region. The practicalities of delivery to small groups of
cattlemust surely be a research priority. It is understood that GALVmed
isworkingwith CTTBD on this, and in addition ILRI is reportedly explor-
ing this dilemma. Issues to be addressed include the need to ensure that
straws ﬂush properly, that stability is not affected by the changed for-
mulation, and it requires an amendment to the registration dossiers.6. A synthesis of the MC research to delivery impact continuum
6.1. A review of the chronology of events and the institutions and players
involved
• 1950s to early 1960s: EAVRO under the East African Community
before Kenya's independence. A strong research capacity including
names of Steve Barnett, Peter Bailey, David Brockelsby and others;
• Mid 1960s to mid-1970s: EAVRO post-independence, the UNDP-
supported FAO project led by Matt Cunningham, with a cast of many
including Duncan Brown, Tony Musoke, Roger Purnell, Subhash
Morzaria, Mike Burridge, David Radley, etc. The golden years of ITM
research, and the birth of the MC.
• Late 1970s to early 1990s: The end of the FAO project at EAVRO
Muguga, coincides with the inauguration of ILRAD; the start of the re-
orientation of the ECF vaccine agenda to sporozoite and eventually
schizont vaccines. An exit of resources and scientists from former
EAVRO; a few (such as Alan Young, Tom Dolan) remain at the
renamed NVRI Muguga, and new scientists emerge such as Dadson
Kariuki, Jamlak Mutugi, Alice Maritim, Priscilla Ngumi, Sammy
Ndungu, Sam Mbogo. Period focuses on reﬁning the ITM technique,
studying the parasite dynamics and strain variation, and developing
molecular tools to reﬁne the ITM procedure. The start of the wilder-
ness years with respect to ﬁeld application of ITM
• 1980s to late 1990s: Multiple initiatives in other countries of the
region. Inputs in funding and projects from the Netherlands, Belgium,
DANIDA, UK. Studies in Tanzania, Uganda, Zambia, Zimbabwe. A series
of valuable regional workshops on ECF epidemiology initiated, coordi-
nated by ILRAD, FAO and conducted under the auspices of AU/IBAR.
ILRAD and ILCA become ILRI, under new leadership. The ﬁrst commer-
cial scale MC batch produced at ILRI. The wilderness years continue.
• The Noughties: The DFID study of animal health research priorities for
poverty reduction leads to the birth of a Public Private Partnership of
what was to become GALVmed. The wilderness years continue, as ILRI
produces a newbatch ofMC at the request of AU/IBAR. AU/IBAR chaired
an ECF regional task force, comprising government representatives of
the four countries currently using the ECF MC vaccine (Malawi, Kenya,
Tanzania and Uganda), GALVmed, ILRI and Pan-African Veterinary
Vaccine Centre (PANVAC); opened tenders for MC manufacture
and distribution. Manufacture won by CTTBD. The wilderness
years continue.
• The Twenty-tens: GALVmed moves into a coordinating and facili-
tating role both for the rehabilitation of CTTBD and the extension
of new MC initiatives into other countries in the region with
renewed ﬁnancial support from DFID and BMGF. GALVmed also
pursues registration of MC in different countries. New delivery
initiative launched in Tanzania with USAID support. Private sector
delivery strengthened in Kenya with variable results based on
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sectors. Still no recombinant vaccine alternative emerging.
6.2. The innovation to impact pathway: some lessons learned
The ITM innovation, in particular the MC, has indeed had many
direct and indirect impacts, which have been presented and discussed
above. The direct impacts on cattle have been survival of animals, and
have thus contributed to the livelihoods of many who have had their
cattle immunised. The indirect impacts have been many, in some cases
of greater long term contribution to science and capacity development.
However, importantly, the direct impacts have not been on the scale
that they could have been, nor in the production systems inwhich there
is arguably the greatest need, nor over the time scale they could have
been anticipated. The following overarching issues are considered to
have been the principle contributors to these inadequacies.
• A supply-driven, not demand-driven, approach to vaccine deploy-
ment has characterised ITM. The technology has been promoted by
the handful of scientists engaged with ECF control. This has left a fun-
damental weakness in the understanding of the different livestock
production systems in the countries of the region, and most impor-
tantly of the business aspirations of producers, farmers, pastoralists
and health service providers embedded in the ECF-endemic environ-
ment. This aspect of development sciencewas almost totally absent in
the early days of independence, concurrent with the early ITM tech-
nology successes, and a current vision of the evolving and intensifying
livestock production systems, as well as their complex idiosyncrasies
in terms of technology adoption, remains grossly inadequate.
• The void in leadership and responsibility to ensure sustainable MC
stabilate production. It is argued by some that inadequate advantage
was taken of the 1996 milestone of MC production at a commercial
scale by ILRI, and particularly ten years later with production of the
ILRI 08 batch in 2007. ILRI was generally considered to be (and some
argue remains) the only institution in the region with the human,
ﬁnancial and technical resources necessary for the complex MC pro-
duction process. Some have argued that ILRI even had an international
responsibility to take a leadership role and continue producing
stabilates. Opposing this was ILRI's management at the time, which
felt that moving into vaccine production was a risk to ILRI's role and
credibility as an international research institute. Furthermore ILRI is
not a registered vaccine producer and does not have the structures
to monitor and oversee vaccine production required to meet GMP
guidelines. In addition, certain of the regional government authorities
supported what they saw to be a more politically correct pathway of
MC production under the auspices of AU/IBAR, which ILRI readily
bought into. With hindsight, these two forces arguably conspired to
circumvent the pragmatic decision in the public interest for ILRI to
pick up the responsibility for ITM production, which some consider
belonged to ILRI.
• The merits of the new public private partnership, combined with the
inadequacies and politics of the constituents it was given to work
with. The ITM was in part responsible for the birth of GALVmed, by
being one of the technologies identiﬁed in the DFID-sponsored
analysis of animal health research priorities for poverty reduction.
GALVmed has built up a portfolio of priority technologies for it to
promote, and has successfully raised considerable funding to help
move these to the ﬁeld. GALVmed entered the stage concurrent with
ILRI's production ofMC batch ILRI 08.With ILRI not wishing to contin-
ue with ITM production, GALVmedwelcomed the opportunity to take
on a leadership role in this, and to start developing its own position in
African livestock technology development and deployment.While the
relationshipwith ILRI is nowgenerally seen to be functional on several
fronts (with ILRI collaborating closely in assistance to CTTBD, and
GALVmed working with ILRI in the ECF consortium, for example),this relationship was strained in the early twenty-tens. GALVmed
leadership at the time was seeking to broaden its funding base
through partnerships with major donors, but some observers
considered that it did not engage adequately with ILRI, and was
seen as a new competitor for the scarce global funds for animal health
technologies in developing countries. In addition, there was a
corresponding reluctance from ILRI, particularly at the scientist
level, to explore dialogue with the “new kid on the block”. An
independent study of ILRI's biosciences research opportunities and
comparative advantage commissioned in 2012 by the incoming
Director General concluded “there is overall weakness in some areas
in establishing partnerships with downstream partners and interna-
tional organisations, and indeed in understanding the need for such
engagement. This is particularly the case with GALVmed, where
very little functional partnership seems to exist”. Fortunately, as
emphasised above, these inadequacies of communication on both
sides now appear to be in the past, and the two institutions have
deﬁned much more clearly their differential roles, ILRI in research
and GALVmed in development and market creation.
• In this environment, andwithAU/IBARadvocating its role as anumbrel-
la for future ITM deployment, GALVmed then helped oversee a tender
process under AU/IBAR for regional ITM production, in which CTTBD
emerged the winner. While GALVmed undoubtedly welcomed its
new role as a key player, it then had to deal with the reality of resusci-
tating a twice-collapsed institution, and do this in a politically charged
environment. At the beginning of this process there was sufﬁcient of
the ILRI 08 batch to satisfy the needs of the region, but thiswas followed
by a shortage of ECF-ITM in 2014. On top of this the re-equipping of
CTTBD took about three years. It is fully understandable that GALVmed
took its time with the resuscitation process, and ensured that its ﬁrst
vaccine batch (MCL 01) was produced before opening the doors to
the world's media in December 2014.
• Were thewilderness yearswasted? Yes theywere in terms of the direct
impact of ITM, but with hindsight they played an important role in
broadening the understanding of ECF epidemiology and control at a
regional level, bring all countries and their scientists together, and in
raising the awareness, standard and proﬁle of many key African scien-
tists who now hold important positions in many public and private
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